A way to catch the disease before it becomes a death sentence
Each day in Wisconsin, three people receive a pancreatic cancer diagnosis, and two of them will not survive it — a quiet tragedy that has persisted largely because the disease reveals itself only after it has already spread beyond reach. A health company called Grail has developed a blood test named Galleri that may begin to change this calculus, offering the possibility of detecting more than fifty cancer types in their earliest stages by reading the molecular signals cancer leaves in the bloodstream. The test is not yet approved by the FDA nor covered by insurance, but it stands at the threshold of a moment when early detection could become as ordinary as a routine checkup — and for cancers that have long hidden in silence, that threshold matters enormously.
- Pancreatic cancer kills two out of every three patients diagnosed in Wisconsin daily, largely because it is almost never caught before it has already advanced to a late, harder-to-treat stage.
- Grail's Galleri test analyzes DNA shed by cancer cells into the bloodstream and can identify over fifty cancer types early — including pancreatic cancer — with a false positive rate below one percent.
- At $949 per test and without FDA approval or insurance coverage, access remains a significant barrier for the patients who could benefit most.
- Pending legislation in both the House and Senate could require Medicare to cover any FDA-approved early detection tests, potentially opening the door to routine use during annual physicals.
- Grail's own Julia Feygin, who lost her father to pancreatic cancer at fourteen, embodies the human urgency behind the science — the test is not just a product but a response to a deeply personal and widely shared grief.
In Wisconsin, three people are diagnosed with pancreatic cancer every day. Two of them will die from it. That grim reality is what gives Grail's announcement about its new blood test, Galleri, its particular weight.
Galleri works by detecting DNA shed by cancer cells into the bloodstream, identifying patterns that signal malignant growth and pinpointing where in the body it originated. It can detect more than fifty cancer types — including pancreatic cancer, which typically hides until stage three or four — with a false positive rate below one percent. More than 140 studies have validated the approach. The test costs $949 and returns results in about ten business days.
Julia Feygin, a senior medical science liaison at Grail, brings a personal dimension to the work. She was fourteen when her father died of pancreatic cancer, and she joined the company because she understood what early detection could mean. The test, she emphasizes, is not meant to replace mammograms or colonoscopies, but to serve as an additional tool — a way to see what existing screenings might miss.
The road ahead includes FDA approval, which is still pending, and insurance coverage, which has not yet materialized. Steve Lipshetz of the Milwaukee Pancreatic Cancer Action Network points to legislation moving through Congress that would require Medicare to cover any FDA-approved early detection test — a shift that could make Galleri a routine part of the annual physical.
The larger vision is simple: catch cancer before it spreads, when treatment still has room to work. For diseases like pancreatic cancer, where the current standard amounts to diagnosing a fire after the house has already burned, that would be a profound change.
In Wisconsin, three people learn they have pancreatic cancer every single day. Two of them will die from it. That grim arithmetic is what makes the announcement from Grail, a health company, feel like something worth paying attention to.
The company has developed a blood test called Galleri that can identify more than fifty different types of cancer in their earliest stages—including pancreatic cancer, which typically hides until it has already reached stage three or four, when treatment options narrow and survival rates plummet. The test works by analyzing DNA shed by cancer cells into the bloodstream, looking for patterns that distinguish malignant growth from the normal cellular churn of a healthy body. When researchers spot those patterns, they can not only confirm cancer is present but predict with high accuracy where in the body it originated.
The clinical evidence is substantial. More than 140 studies have validated the approach, and the test maintains a false positive rate below one percent—meaning it rarely sends patients on wild goose chases for cancers that don't exist. At $949 per test, it's not cheap, but for a disease like pancreatic cancer, where early intervention can mean the difference between life and death, the cost begins to look reasonable.
Julia Feygin, a senior medical science liaison at Grail, speaks about the test with the clarity of someone who has lived the stakes. She was fourteen when her father died of pancreatic cancer. She joined Grail because she understood viscerally what the company's mission meant: a way to catch the disease before it becomes a death sentence. "There's this really big unmet need," she explained, "to have a test that can detect as many different cancer types as possible at earlier stages so that patients can get into their health care provider and get treatment earlier."
The test is not meant to replace existing cancer screenings—mammograms, colonoscopies, and the rest. Rather, it functions as an additional tool, a way for doctors to narrow their diagnostic focus and move faster toward treatment. Once blood is drawn, it travels to a Grail laboratory for processing, with results arriving in about ten business days.
There are hurdles ahead. The Food and Drug Administration has not yet approved Galleri, though Grail is working through that process. Insurance companies are not currently covering it, though that too is under negotiation. Steve Lipshetz, who works with the Milwaukee Pancreatic Cancer Action Network, points to pending legislation in both the House and Senate that would require Medicare to automatically cover any early detection tests approved by the FDA—a policy shift that could transform access.
The vision is straightforward: a day when a blood test for early cancer detection becomes as routine as checking cholesterol during an annual physical. Not a replacement for vigilance or existing screening protocols, but an additional lens through which to see what might be growing in the dark. For a disease like pancreatic cancer, where the current standard is to diagnose it only after it has already spread, that would represent a fundamental change in how the disease is fought.
Citações Notáveis
There's this really big unmet need to have a test that can detect as many different cancer types as possible at earlier stages so that patients can get into their health care provider and get treatment earlier.— Julia Feygin, Senior Medical Science Liaison at Grail
It would be a huge breakthrough to have a test that proves accurate that might one day be given routinely when you go in for your annual physical and your blood test.— Steve Lipshetz, Milwaukee Pancreatic Cancer Action Network
A Conversa do Hearth Outra perspectiva sobre a história
Why does pancreatic cancer stay hidden so long?
It grows deep inside the body, surrounded by other organs. By the time someone feels sick enough to see a doctor, the cancer has usually already spread. There's no routine screening for it like there is for breast or colon cancer.
So this blood test is looking for cancer DNA floating around in the bloodstream?
Exactly. Cancer cells shed their DNA into the blood as they grow. The test sequences that DNA and looks for patterns that don't match healthy cells. It's like finding a specific fingerprint in a crowd.
Less than one percent false positives sounds almost too good. How is that possible?
They've run over 140 clinical studies. The test has been refined through massive amounts of data. But it's also important to remember: a negative result doesn't mean you're definitely cancer-free. It's a tool, not a guarantee.
Why isn't insurance covering it yet?
It's new. Insurance companies need time to evaluate whether the benefit justifies the cost. There's also a question of whether routine screening for fifty cancer types makes sense for everyone, or just high-risk populations.
What happens after someone gets a positive result?
The test can tell doctors where the cancer signal is coming from. That gives them a direction for more targeted diagnostic work—imaging, biopsies, whatever makes sense. It speeds up the process instead of sending them on a fishing expedition.
Does this change how we think about cancer prevention?
It shifts the conversation from prevention to early detection. You can't prevent cancer you don't know about. But if you catch it at stage one instead of stage four, your chances improve dramatically. That's the real promise here.